Aleddra Emergency T8 and T5 LED Lamps Gain Industry-Wide Adoption

Best-selling Emergency LED T8 and T5 lamps from Aleddra

Aleddra announced that its Emergency LED T8 & T5 tubes have gained wide adoption across multiple market segments: industrial, education, and federal entities.

Aleddra has seen a number of their existing customers switch from the G2/G3 EM T8 to the NEW G4 EM T8. Why? Because of the G4’s ability to self-testing/self-diagnosis.”

— Matthew Maa

RENTON, WASHINGTON, UNITED STATES, October 22, 2020 /EINPresswire.com/ — Aleddra, a Seattle-based lighting technology company, is pleased to announce that with the help of its distribution partners its Emergency LED T8 & T5 tubes have gained wide adoption across multiple market segments: industrial, education, and federal entities. Below are a few examples:

• An Amazon distribution center located in Ohio tested the Aleddra Gen3 Emergency T8 in early September. Before the end of September, Graybar order over (600) G3 EM tubes for that facility.
• In Missouri, a school district with (32) schools began ordering the Aleddra Gen2 Emergency T8 through Rexel. Why? Because they discovered it was less expensive to purchase the G2 EM as compared to purchasing and installing an emergency ballast. Because of the cost savings to the district this district has been able to accelerate the purchasing/installation of Aleddra G2 EM T8 tube.
• US Department of State announced two large RFQ’s (request for quote) for several Aleddra EM T8 in September on the new federal project bid board: UNISON Marketplace.
o Buy #: 1047284_02, Solicitation #: 8650-2023103
o Buy #: 1045815_01, Solicitation #: 8650-2023013

“Aleddra has seen a number of their existing customers switch from the G2/G3 EM T8 to the NEW G4 EM T8. Why? Because of the G4’s ability to self-testing/self-diagnosis,” stated Dr. Matthew Maa, Aleddra’s VP Sales & Marketing.” Dr. Maa anticipates this transition to accelerate as more individuals/companies look for ways to reduce maintenance costs on their emergency lighting protocols.

BENEFITS of the Aleddra Emergency LED T8 & T5 tubes:

• Aleddra EM tubes are all 2-in-1 EM tube: They operate as both a standard LED tube as well as an Emergency LED tube.
• The built-in Lithium battery is designed to last (90+) minutes.
• 40-50% cost savings as compared to purchasing an emergency ballast.
• Eliminates the need for the emergency ballast(s) as well as standard ballast(s).
• 90% labor savings on replacement (plug & play)
• For the G4 there is 90% operation savings on monthly/annual emergency lighting equipment audit.

Aleddra offers these EM T8/T5 products:

• 2-ft G3 EM T8: simple ballast bypass for always-on application, https://www.aleddra.com/gen-3-emergency-t8-tube/
• 4-ft G3 EM T8: simple ballast bypass for always-on application, https://www.aleddra.com/gen-3-emergency-t8-tube/
• 4-ft G2 EM T8: can be turned on/off by a wall switch, ideal for offices/classrooms, https://www.aleddra.com/g2-emergency-t8-tube/
• 4-ft G2 EM T5: can be turned on/off by a wall switch, ideal for offices/classrooms, https://www.aleddra.com/emergency-t5-2/
• 4-ft G4 EM T8: new G4 self-testing/self-diagnosis, on/off by a wall switch, https://www.aleddra.com/g4-emergency-t8/

For more information, please email info@aleddra.com or call us at 425-430-4555.

Matthew Maa
Aleddra
4254304555234
email us here
Visit us on social media:
LinkedIn


Source: EIN Presswire

Body Composition Analyzers Market is projected to reach $596 million by 2025, at CAGR of 6.6% Growth Rate

Body Composition Analyzers Market

Body Composition Analyzers

Body Composition Analyzers Market accounted for $356 million in 2017, and is projected to reach $596 million by 2025, registering a CAGR of 6.6% – 2025

North America contributed nearly two-fifth share of the total market in terms of revenue by 2017 and would maintain its lead by 2025”

— Ashish

PORTLAND, OREGON, UNITED STATES, October 23, 2020 /EINPresswire.com/ — The report on the global body composition analyzers market accounted for $356 million in 2017 and is estimated to reach $596 million by 2025, registering a CAGR of 6.6% from 2018 to 2025. The report provides an extensive analysis of drivers & opportunities, key winning strategies, market size & projections, major segments, and competitive landscape.

Rise in obese population, supportive initiatives by governments for promoting healthy lifestyle, and increase in health consciousness among people drive the growth of the market. However, high cost of investment and stringent regulations related to usage of body composition analyzers restrain the market growth. On the other hand, upsurge in the number of gyms and fitness clubs would create new opportunities in the industry.

Request a Sample Copy of the Research Report: @ https://www.alliedmarketresearch.com/request-sample/4294

Frontrunners in the industry

The key market players discussed in the report include Omron Corporation, Hologic, Inc., Cosmed S.R.L., GE Healthcare, Jawon Medical Co., Ltd., Tanita Corporation, Rjl Systems, Inc., Inbody Co., Ltd., Bodystat Ltd., and Seca GmbH & Co. Kg. They have adopted different strategies such as partnerships, expansions, mergers & acquisitions, joint ventures, collaborations, and others to gain a strong position in the industry.

Inquiry for Buying Report @ https://www.alliedmarketresearch.com/purchase-enquiry/7153

North America to maintain its lion's share by 2025

North America contributed nearly two-fifth share of the total market in terms of revenue by 2017 and would maintain its lead by 2025 due to the presence of well-established healthcare infrastructure and continuous R&D initiatives. However, Asia-Pacific would grow at the highest CAGR of 9.0% from 2018 to 2025, owing to the increase in healthcare expenditure, surge in fitness clubs & wellness centers, and rise in obese population across developing countries.

The fitness clubs & wellness centers segment held a major share, contributing for more than two-thirds of the total share in 2017, and is estimated to maintain its pole position by 2025. This is attributed to surge in health consciousness among population and considerable surge in number of health clubs and gyms worldwide. However, the home user segment is expected grow at the largest CAGR of 10.4% during the forecast period, owing to rise in adoption of handheld and portable body composition analyzers for gaining convenience and flexibility in use.

Read More @ https://www.alliedmarketresearch.com/body-composition-analyzers-market

Bio-impedance analyzers to continue its dominance throughout the forecast period

Bio-impedance analyzer segment contributed more than two-fifths of the total market share in 2017 and is expected to continue its dominance throughout the forecast period. This is attributed to low cost and convenience offered by them as compared to other analyzers. However, air displacement plethysmography equipment segment would register the highest CAGR of 9.6% from 2018 to 2025, owing to the higher accuracy provided by them and rise in awareness about bod pods. The research also analyzes skinfold caliper, dual energy X-Ray absorptiometry, hydrostatic weighing equipment, and others.

Similar Reports:

Healthcare CRO Services market Analysis and Industry Forecast, 2026

UV Infection Control Devices Market Analysis and Industry Forecast, 2026

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here


Source: EIN Presswire

Hygieacare presents Real-World Evidence at ACG 2020 – HygiPrep™ is a Dominant Strategy Over Oral Prep for Colonoscopy

odorless and acoustically protected HyGIeaCare experience

Real-World Evidence of >12,000 procedures validate a published economics outcomes study – HygiPrep™ is a Dominant Strategy Over Oral Prep for Colonoscopy

Real-World Evidence has consistently shown that HygiPrep is a dominant strategy over oral prep.
We look forward to payers and patients benefit by reimbursement.”

— Gavriel (Gabi) Meron, Chairman and Chief Executive Officer, HyGIeaCare Inc.

NORFOLK, VIRGINIA, UNITED STATES, October 22, 2020 /EINPresswire.com/ — HyGIeaCare Inc. announced that a poster was presented at the American College of Gastroenterology ACG 2020 VIRTUAL showing data that supports and validates previous published economic outcomes. In 2017, Ananya Das, MD FACG FASGE et al, published that a Monte Carlo simulation predicted lifetime savings to the healthcare system of $150,000,000 for a cohort of 100,000 average-risk patients (age>50) when using HygiPrep compared to oral prep for colonoscopy bowel preparation.
After over 12,000 procedures, Real-World Evidence confirms the model's assumptions and supports its outcome – HygiPrep is a dominant strategy compared to the oral prep.
The model assumptions were compared to real-world evidence collected from 108 physicians who prescribed 12,297 HygiPrep procedures in four independent Hygieacare centers working under proprietary, stringent, and validated standard operating procedures developed at Hygieacare. The parameters that were compared included: the price paid by the patients for HygiPrep (no more than $245), the safety profile of HygiPrep (no serious adverse events), adequacy of HygiPrep as indicated by the endoscopist following colonoscopy (97% adequacy), patients' satisfaction from HygiPrep (97% satisfied/very satisfied) and patients' feedback regarding their willingness to repeat HygiPrep for their next colonoscopy (97%).
In conclusion, after over 12,000 procedures, Real World Evidence confirms the model's assumptions and supports its outcome: High-volume colon irrigation Bowel Prep (HygiPrep) is a dominant strategy compared to oral prep.
The Poster was submitted for presentation at the World Congress of Gastroenterology at ACG 2020 by Richard M. Sperling, MD, and William Stassen, MD, from Austin Gastroenterology, Austin, TX, USA, with Orly Levitan, Ph.D., and Dawn B. Burleson, RN, MBA, CRA, from Hygieacare Inc., Norfolk, VA, USA, Pradeep K. Bekal, MD FACG FASGE, from Ohio Gastroenterology and Liver Institute, Cincinnati, OH, USA, and David A. Johnson, MD MACG, from Eastern VA Medical School, Norfolk VA, USA.

“Real-World Evidence has consistently shown that HygiPrep is a dominant strategy over oral prep for colonoscopy procedures,”
said Gavriel (Gabi) Meron, Chairman and Chief Executive Officer, HyGIeaCare Inc. "Patients have been paying for HygiPrep out of pocket, and we look forward to seeing payers and their patients benefit by approving reimbursement for this recommended and preferred prep."

About American College of Gastroenterology
The ACG is the preeminent professional organization that champions the prevention, diagnosis, and treatment of digestive disorders by facilitating the delivery of the highest quality, compassionate, and evidence-based patient care.
ACG's mission is to enhance its members' ability to provide world-class care to patients with digestive disorders and advance the profession through excellence and innovation based upon the pillars of Patient Care, Education, Scientific Investigation, Advocacy, and Practice Management.
More than 15,000 physicians are members of the ACG. The ACG provides its members with the most accurate and up-to-date scientific information on digestive health and the etiology, symptomatology, and treatment of GI disorders through annual scientific meetings, its peer-reviewed The American Journal of Gastroenterology, regional postgraduate training courses, and research grants.

# # # # # #

About HyGIeaCare, Inc.
The Company's mission is to bring the HyGIeaCare FDA-cleared Prep System and solutions exclusively to the GI world.
The goal of HyGIeaCare is to provide unique services and solutions to gastroenterologists to deliver better GI outcomes for their patients and their practice through collaborations between hospitals, medical centers, GI physicians, researchers and HyGIeaCare Centers to be established in the US and throughout the world.

Michal Gorodish, VP Marketing
hygieacare inc.
+1 470-819-8351
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

HygiPrep


Source: EIN Presswire

PsyTech Announces Lineup for Oct 27 Virtual Summit: "A Global Dialogue on the Future of Psychedelic Medicine"

The PsyTech Summit is fuelling a global dialogue on the future of psychedelic medicine

PsyTech brings together the world’s leaders in Psychedelic Medicine

The free event will be streamed from 8 cities across the globe and feature panels, discussions & insights from thought leaders across the psychedelic community

This is the very beginning of the integration of psychedelic therapeutics into mainstream medicine, and we're proud to bring the psychedelic therapy community together for the PsyTech Summit.”

— PsyTech CEO Hayim Raclaw

TEL AVIV, ISRAEL, October 22, 2020 /EINPresswire.com/ — PsyTech Inc., a leading company advancing medicinal psychedelic research and community engagement, has announced the final lineup for its upcoming PsyTech Summit, titled “A Global Dialogue on the Future of Psychedelic Medicine.” Featuring talks and panels from the top names in the psychedelic medicinal space, the October 27th event will be streamed for attendees from eight cities across the globe. Thousands of attendees are expected at the summit. Click here to register and access the full lineup and agenda.

PsyTech was founded in 2019 with the mission of accelerating the acceptance and good use of psychedelic-assisted therapy through global conferences, community building, education, and clinical solutions. The summit will feature leaders in psychedelic research, therapy, technology, advocacy, and business. Headlining speakers will include Rick Doblin, founder and executive director of MAPS, Professor Matthew Johnson of Johns Hopkins University, author, psychiatrist, and psychopharmacologist Dr. Julie Holland, and Dr. Robin Carhart-Harris, founder of the Centre for Psychedelic Research at Imperial College London.

PsyTech CEO Hayim Raclaw said, “These exciting times are the very beginning of the integration of psychedelic therapeutics into mainstream medicine, and we’re proud to bring the psychedelic therapy community together for the PsyTech Summit. It will give a platform to those who have spent decades working for the good use of these molecules to help people, as well as the latest researchers, therapists, advocates, and business leaders. Enabled by our sponsors – the leading companies in psychedelics – and provided at no cost to all attendees, this Summit will be a benchmark event. We’re grateful to all involved for bringing it to fruition.”

Entheon Biomedical, a psychedelic research and drug development company focused on treating substance abuse disorders, has signed on as one of the summit’s host sponsors. Entheon’s CEO, Timothy Ko, said, "We are honored to sponsor PsyTech Summit. Psychedelics are at a critical crossroads and we are excited to be part of a unique showcasing of the scientific, regulatory and business progress that is rapidly taking shape in the space."

"Novamind is proud to sponsor the PsyTech Summit and to contribute to the dialogue on clinical and research developments in psychedelic medicine,” said Yaron Conforti, CEO and Director of Novamind, a mental health and wellness company specializing in psychedelic-assisted psychotherapy.

The psychedelic clinical market is projected to grow at a CAGR of 16.3% over the next eight years to reach $6.85 billion by 2027, according to Data Bridge Market Research. There are now over 1000 psychedelic-assisted therapy clinics and retreats around the world, with expected growth of over 2000 new clinics in the coming years.

PsyTech is proud to partner with many of the top organizations in the psychedelics space for its upcoming summit.

About PsyTech
Venture-backed PsyTech is the leading therapeutic psychedelics community builder and venture developer in education, training, and clinical solutions. Its chief goals are to promote safe and effective psychedelic health and wellness, combat stigma, and accelerate innovation. Empowered by the advancements of ground-breaking clinical research, PsyTech fosters and steers innovation in psychedelics to serve the greater good.

Cory Jones
PsyTech
+1 (718) 781-4894
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

PsyTech Announces Lineup for Oct 7 Virtual Summit: "A Global Dialogue on the Future of Psychedelic Medicine"

The PsyTech Summit is fuelling a global dialogue on the future of psychedelic medicine

PsyTech brings together the world’s leaders in Psychedelic Medicine

The free event will be streamed from 8 cities across the globe and feature panels, discussions & insights from thought leaders across the psychedelic community

This is the very beginning of the integration of psychedelic therapeutics into mainstream medicine, and we're proud to bring the psychedelic therapy community together for the PsyTech Summit.”

— PsyTech CEO Hayim Raclaw

TEL AVIV, ISRAEL, October 22, 2020 /EINPresswire.com/ — PsyTech Inc., a leading company advancing medicinal psychedelic research and community engagement, has announced the final lineup for its upcoming PsyTech Summit, titled “A Global Dialogue on the Future of Psychedelic Medicine.” Featuring talks and panels from the top names in the psychedelic medicinal space, the October 27th event will be streamed for attendees from eight cities across the globe. Thousands of attendees are expected at the summit. Click here to register and access the full lineup and agenda.

PsyTech was founded in 2019 with the mission of accelerating the acceptance and good use of psychedelic-assisted therapy through global conferences, community building, education, and clinical solutions. The summit will feature leaders in psychedelic research, therapy, technology, advocacy, and business. Headlining speakers will include Rick Doblin, founder and executive director of MAPS, Professor Matthew Johnson of Johns Hopkins University, author, psychiatrist, and psychopharmacologist Dr. Julie Holland, and Dr. Robin Carhart-Harris, founder of the Centre for Psychedelic Research at Imperial College London.

PsyTech CEO Hayim Raclaw said, “These exciting times are the very beginning of the integration of psychedelic therapeutics into mainstream medicine, and we’re proud to bring the psychedelic therapy community together for the PsyTech Summit. It will give a platform to those who have spent decades working for the good use of these molecules to help people, as well as the latest researchers, therapists, advocates, and business leaders. Enabled by our sponsors – the leading companies in psychedelics – and provided at no cost to all attendees, this Summit will be a benchmark event. We’re grateful to all involved for bringing it to fruition.”

Entheon Biomedical, a psychedelic research and drug development company focused on treating substance abuse disorders, has signed on as one of the summit’s host sponsors. Entheon’s CEO, Timothy Ko, said, "We are honored to sponsor PsyTech Summit. Psychedelics are at a critical crossroads and we are excited to be part of a unique showcasing of the scientific, regulatory and business progress that is rapidly taking shape in the space."

"Novamind is proud to sponsor the PsyTech Summit and to contribute to the dialogue on clinical and research developments in psychedelic medicine,” said Yaron Conforti, CEO and Director of Novamind, a mental health and wellness company specializing in psychedelic-assisted psychotherapy.

The psychedelic clinical market is projected to grow at a CAGR of 16.3% over the next eight years to reach $6.85 billion by 2027, according to Data Bridge Market Research. There are now over 1000 psychedelic-assisted therapy clinics and retreats around the world, with expected growth of over 2000 new clinics in the coming years.

PsyTech is proud to partner with many of the top organizations in the psychedelics space for its upcoming summit.

About PsyTech
Venture-backed PsyTech is the leading therapeutic psychedelics community builder and venture developer in education, training, and clinical solutions. Its chief goals are to promote safe and effective psychedelic health and wellness, combat stigma, and accelerate innovation. Empowered by the advancements of ground-breaking clinical research, PsyTech fosters and steers innovation in psychedelics to serve the greater good.

Cory Jones
PsyTech
+1 (718) 781-4894
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Stori™, the smart cannabis storage company, integrates Boveda®, the global leader in 2-way humidity control

Stori joined with Boveda to empower cannabis consumers and patients with the best-in-class cannabis storage solution that protects terpenes from evaporation.

TORONTO, ONTARIO, CANADA, October 22, 2020 /EINPresswire.com/ — Stori joined with Boveda to empower cannabis consumers and patients with the best-in-class cannabis storage solution that protects terpenes from evaporation.

Stori is a purpose-built cannabis storage device designed for cannabis consumers and patients who want to stop hiding their cannabis. To fight cannabis stigma, Stori created a stylish storage solution that complements today’s home décor. Now, consumers can proudly display their cultivars in their living spaces. Keeping flower at hand is much more practical—and convenient—than stowing it away in Mason jars, Ziploc® bags or shoeboxes.

Stori comes with a Case that holds six Pods and six Tubes. Made from food-safe aluminum, the Pods and Tubes can store a variety of cannabis products, including flower, edibles, concentrates, capsules, and vape pods. The airtight Pods, which hold up to seven grams of cannabis, are custom designed to hold the enclosed humidity control in their lids. This holder ensures that the Boveda stays securely in place when consumers access their flower.

“The humidity pack holder was one of the great suggestions we got from consumers and patients we interviewed. It was clear that maintaining quality was a top priority, and relevant to frequent and occasional consumers. This is why we’re so excited about our partnership with Boveda, as they are synonymous with quality and the trusted source when it comes to humidity packs,” said Karina Karassev, Co-Founder of Stori.

Boveda is a patented 2-way humidity control for moisture-sensitive products, such as cannabis. Only Boveda can create a monolayer shield of purified water over the trichome to protect terpenes from evaporation and degradation. Even in an airtight cannabis container like Stori Pods, 40% of terpenes can be lost in a week without the protection of a terpene shield. Terpenes are the organic compounds responsible for the aroma and flavors in cannabis and influence its effects. Saving terpenes, consumers enjoy a better, smoother and more enjoyable experience.

Based on maintaining the ideal humidity conditions that protect flower, Boveda automatically adds and removes moisture as needed. Boveda is FDA-compliant and contains an all-natural saltwater solution in its packaging membrane.

“Stori recognized that style and substance go hand-in-hand when designing this innovative cannabis container,” said Sean Knutsen, president and CEO, Boveda Inc. “Most people don’t realize that without precise 2-way humidity control terpenes continually evaporate from cannabis, even while in airtight containers. Lost terpenes mean lost aroma, flavor, and efficacy. Integrating Boveda into the Stori Pod lid creates a microscopic layer of water molecules around the trichomes to serve as a terpene shield. With it, you’ll enjoy an unparalleled experience that’s safe, effective, and pleasurable.”

Stori’s collaboration with Boveda is perfect timing for holiday gift-giving. Both Stori and Boveda companies have a number of activities planned for the 2020 holiday season and beyond, with a goal to help consumers stop hiding cannabis, and save the terps.

To learn more please visit yourstori.com/boveda

About Boveda
Boveda is The Original Terpene Shield™. Consumers use Boveda to protect the passions in life—from top-shelf cannabis and premium cigars to wooden fretted and stringed musical instruments. Through Boveda’s all-natural salt solution, moisture-sensitive products are protected faster and for longer periods of time. Placing Boveda in a cannabis storage container, humidor or instrument case, gives consumers confidence they’re doing everything they can to achieve quality and excellence and prevent humidity fluctuations from degrading the things they love most.

About RCU – Responsible Cannabis Use
RCU – Responsible Cannabis Use is a cannabis education company offering a number of educational products including Stori, the smart cannabis storage. RCU offers Stori to consumers, retailers, and brands looking to fight cannabis stigma with safety, function, and design.

To learn more about RCU, visit thercu.org, follow RCU on Twitter, Facebook, and Instagram.
To learn more about Stori, visit yourstori.com, follow Stori on Facebook and Instagram.

Afshin Mousavian
RCU – Responsible Cannabis Use
+1 416-879-2873
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

SpiraLinks Migrates FocalReview® Planning Suite IT Infrastructure To The AWS Cloud

logo

SpiraLinks logo

SpiraLinks has moved its FocalReview® planning suite IT infrastructure to the AWS Cloud to meet evolving challenges for compliance and data protection/privacy

CAMPBELL, CA, USA, October 22, 2020 /EINPresswire.com/ — SpiraLinks has migrated its infrastructure to the AWS Cloud, with the expert guidance of Effectual. SpiraLinks recognized that a successful migration would provide an opportunity to modernize its technology stack and leverage new AWS capabilities to better serve its clients.

The migration to an AWS environment has increased efficiencies, improved security and compliance, and optimized costs. In addition, SpiraLinks wanted to access new AWS Native services to modernize and evolve its business. To achieve these business objectives, SpiraLinks partnered with Effectual to lead its migration and modernization efforts. Effectual is a cloud first, security first managed and professional services company and AWS Premier Consulting Partner with deep expertise leading complex migrations and managing modern cloud environments across VMware, VMware Cloud on AWS, and native AWS environments.

Through its partnership with Effectual, SpiraLinks was able to achieve a rapid migration of its infrastructure to the AWS Cloud and avoid unexpected downtimes associated with the closure of its MSP’s data center. The migration to an AWS environment provided opportunities to improve security, increase efficiencies, and optimize costs while opening new pathways to modernizing using AWS native services and capabilities.

Moving forward, SpiraLinks will utilize the newer, more secure AWS environment for its many tools and benefits in accordance with the constantly changing business and operational requirements of the SpiraLinks client base, with the watchful guidance of Effectual. Specifically, compliance and data protection/privacy will be evolving challenges for SpiraLinks and the client base. The AWS environment has been chosen as an excellent “base of operations” to meet those challenges. and Effectual the team to manage.

SpiraLinks offers tailored consulting services for Fortune 500 companies, including designing, installing, and hosting secure web-based systems for human resources, compensation, and finance teams. The company’s FocalReview® planning suite has long been known as a leader in compensation and performance management, supporting customers in the US and beyond.

JULIE SOUTHERN
SpiraLinks Corporation
+1 408-608-6900
email us here
Visit us on social media:
LinkedIn


Source: EIN Presswire

Bottled Water Market is Estimated to Experience a Notable Rise in the Span of Coming Years

Bottled Water Market

Bottled Water Market

Rising health awareness, convenience of use, premium quality and taste, and availability of functional water in different flavors fuel the growth of the market.

PORTLAND, OREGON, UNITED STATES, October 22, 2020 /EINPresswire.com/ — Rising health awareness, convenience of use, premium quality and taste, and availability of functional water in different flavors fuel the growth of the global bottled water market. On the other hand, stringent regulations for the bottled water, harmful effects of using plastic bottles, and availability of tap water at lower cost impede the growth to some extent. Nevertheless, changing life style patterns of consumers is expected to create lucrative opportunities in the industry.

According to the report published by Allied Market Research, the global bottled water market was estimated at $169.86 billion in 2015 and is expected to hit $319.86 billion by 2022, registering a CAGR of 9.5% from 2014 to 2022. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends.

Download PDF Brochure: https://www.alliedmarketresearch.com/request-sample/1802

Covid-19 scenario-
• Bottled water that is readily available in supermarkets and retail stores experienced a decline in its demand from consumers, as most of the stores were brought to closure during the first phase of the lockdown.
• Also, disruptions in the supply chain and shortage in raw materials have negatively impacted the market.
• However, with the existing regulations being eased off gradually in most of the countries, the market is expected to get back to its position soon.

The global bottled water market is analyzed across product type and geography. Based on product type, the functional water bottle segment held the highest share in 2015 and is expected to rule the roost by the end of 2022. The same segment is also expected to register the fastest CAGR throughout the forecast period. The other segments analyzed in the research report include carbonated water, flavored water, and still water.

Get Detailed COVID-19 Impact Analysis on the Bottled Water Market @ https://www.alliedmarketresearch.com/request-for-customization/1802?reqfor=covid

Based on region, Asia-Pacific would remain lucrative till 2022. The region held the largest share in 2015 and is also expected to portray the fastest CAGR OF 10.6% by 2022. The other provinces studied in the report include North America, Europe, and LAMEA.

The key market players analyzed in the global bottled water market report include Hangzhou Wahaha Group Co., Ltd., Dasani, Mountain Valley Spring Company, Nestlé Waters, Danone, PepsiCo Inc., Natural Waters of Viti Ltd., Icelandic Glacial Inc., and The Coca Cola Company.These market players have embraced several strategies including partnership, expansion, collaboration, joint ventures, and others to highlight their prowess in the industry.

Interested in Procuring this Report? Visit Here: https://www.alliedmarketresearch.com/bottled-water-market/purchase-options

About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Cancer Treatment Drugs Market Major Manufacturers, Trends, Sales, Supply, Demand, Share Analysis to 2026

New Study Reports “Cancer Treatment Drugs Market 2020 Global Market Opportunities, Challenges, Strategies and Forecasts 2026” has been Added on WiseGuyReports.

PUNE, MAHARASHTRA, INDIA, October 22, 2020 /EINPresswire.com/ — Cancer Treatment Drugs Market 2020-2026

New Study Reports “Cancer Treatment Drugs Market 2020 Global Market Opportunities, Challenges, Strategies and Forecasts 2026” has been Added on WiseGuyReports.

Introduction/Report Summary:

This report provides in depth study of “Cancer Treatment Drugs Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Cancer Treatment Drugs Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

Cancer Treatment Drugs are used to treat malignancies, or cancerous growths. Depending on the technology it cans classification into Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy and Others.

Key Players

The report has profiled some of the Important players prevalent in the global like – Roche, Novartis, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, Pfizer, Takeda, Eli Lilly, AstraZeneca, Astellas, Merck & Co., Sanofi, Bayer, Biogen Idec, Eisai, Teva, Otsuka, Merck KGaA, Ipsen, AbbVie, Gilead Sciences and more.

This report covers the sales volume, price, revenue, gross margin, manufacturers, suppliers, distributors, intermediaries, customers, historical growth and future perspectives in the Cancer Treatment Drugs.

Request for Free Sample Report of “Cancer Treatment Drugs” Market @ https://www.wiseguyreports.com/sample-request/4787989-global-cancer-treatment-drugs-market-research-report-2020

Market Segmentation based On Type, Application and Region:

The global Cancer Treatment Drugs is analyzed for different segments to arrive at an insightful analysis. Such segmentation has been done based on type, application, and region.

Based on type, the global Cancer Treatment Drugs Market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy (Biologic Therapy) and other

Based on application, the Cancer Treatment Drugs Market is segmented into Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory/Lung Cancer, Other Cancers and Others.

Based on Detailed Regional Analysis, the regional segmentation has been carried out for regions of U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America. The report on WGR includes an in-depth study of the Cancer Treatment Drugs in each regional segment mentioned above.

Key Stakeholders
Cancer Treatment Drugs Market Manufacturers
Cancer Treatment Drugs Market Distributors/Traders/Wholesalers
Cancer Treatment Drugs Market Subcomponent Manufacturers
Industry Association
Downstream Vendors

If you have any special requirements, please let us know and we will offer you the report as you want.

Complete Report Details@ https://www.wiseguyreports.com/reports/4787989-global-cancer-treatment-drugs-market-research-report-2020

Major Key Points from Table of Content:

1 Cancer Treatment Drugs Market Overview
1.1 Product Overview and Scope of Cancer Treatment Drugs
1.2 Cancer Treatment Drugs Segment by Type
1.2.1 Global Cancer Treatment Drugs Sales Growth Rate Comparison by Type (2021-2026)
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy
1.2.5 Hormonal Therapy (Biologic Therapy)
1.2.6 Others
1.3 Cancer Treatment Drugs Segment by Application
1.3.1 Cancer Treatment Drugs Sales Comparison by Application: 2020 VS 2026
1.3.2 Blood Cancer
1.3.3 Breast Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Respiratory/Lung Cancer
1.3.7 Other Cancers
1.4 Global Cancer Treatment Drugs Market Size Estimates and Forecasts
1.4.1 Global Cancer Treatment Drugs Revenue 2015-2026
1.4.2 Global Cancer Treatment Drugs Sales 2015-2026
1.4.3 Cancer Treatment Drugs Market Size by Region: 2020 Versus 2026

…..

6 Company Profiles and Key Figures in Cancer Treatment Drugs Business
6.1 Roche
6.1.1 Corporation Information
6.1.2 Roche Description, Business Overview and Total Revenue
6.1.3 Roche Cancer Treatment Drugs Sales, Revenue and Gross Margin (2015-2020)
6.1.4 Roche Products Offered
6.1.5 Roche Recent Development
6.2 Novartis
6.2.1 Novartis Cancer Treatment Drugs Production Sites and Area Served
6.2.2 Novartis Description, Business Overview and Total Revenue
6.2.3 Novartis Cancer Treatment Drugs Sales, Revenue and Gross Margin (2015-2020)
6.2.4 Novartis Products Offered
6.2.5 Novartis Recent Development
6.3 Celgene
6.3.1 Celgene Cancer Treatment Drugs Production Sites and Area Served
6.3.2 Celgene Description, Business Overview and Total Revenue
6.3.3 Celgene Cancer Treatment Drugs Sales, Revenue and Gross Margin (2015-2020)
6.3.4 Celgene Products Offered
6.3.5 Celgene Recent Development
6.4 Bristol-Myers Squibb
6.4.1 Bristol-Myers Squibb Cancer Treatment Drugs Production Sites and Area Served
6.4.2 Bristol-Myers Squibb Description, Business Overview and Total Revenue
6.4.3 Bristol-Myers Squibb Cancer Treatment Drugs Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Bristol-Myers Squibb Products Offered
6.4.5 Bristol-Myers Squibb Recent Development

and more

Continued…

Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
646-845-9349
email us here


Source: EIN Presswire

Deep Instinct: The Economic Value of Prevention in the Cyber Security Lifecycle

LONDON, 10/2020 – As more employees are now working from home, the attack surface is more complex and widely spread, making prevention even harder to achieve.

LONDON, OXFORDSHIRE, UNITED KINGDOM, October 22, 2020 /EINPresswire.com/ — Deep Instinct: The Economic Value of Prevention in the Cyber Security Lifecycle
 
As more employees are now working from home, the attack surface is more complex and widely spread, making prevention even harder to achieve. In this difficult time, we highlight the implications of the groundbreaking research The Economic Value of Prevention in the Cybersecurity Lifecycle. Conducted by the Ponemon Institute and sponsored by Deep Instinct, the report analyses the cost savings that can be taken in an efficient, zero-time prevention model. Based on responses from over 600 IT and IT security practitioners, how does your experience compare to those of the respondents’? Do you share their sentiment that effective prevention is difficult to achieve? And what do you think are the greatest barriers?
 
Prevention is obviously better than cure, and in this report, we show the benefits that a ‘Prevention-First’ strategy can have on an enterprise environment. Organisations no longer have to assume they will be breached and spend their budgets on remediation and containment. A prevention-first strategy is now a realistic proposition.
 
A highly insightful body of research titled The Economic Value of Prevention in the Cybersecurity Lifecycle. Conducted by the Ponemon Institute and sponsored by Deep Instinct, the report analyses the cost savings that can be taken in an efficient, zero-time prevention model. Results were sourced from over 600 IT and IT security practitioners in NA, who are knowledgeable about their organisations’ cybersecurity technologies and processes. The findings include the approximate cost savings should an effective preventative approach be adopted:
▪ 91% of costs can be eliminated in a nation-state attack, resulting in an average cost saving of $1,366,365
▪ 88% of costs can be eliminated in a zero-day attack, resulting in an average cost saving of $1,089,440
▪ 90% of costs can be eliminated in a ransomware attack, resulting in an average cost saving of $396,675
▪ 82% of cost can be eliminated in phishing attack, resulting in an average cost saving of $682,650
 
Other highlights from the report also found the following:
▪ 70% of respondents believe the ability to prevent would strengthen their security posture.
▪ 55% feel that they are best at containing attacks and this leads to the priority to focus budget on containment, rather than prevention.
▪ 67% of respondents believe the use of automation and advanced AI would improve their ability to prevent.
▪ 50% of respondents say their organizations are wasting limited budgets on investments that don’t improve their security.
The findings of the report address market misconceptions, particularly that an effective preventative approach is difficult to implement and operate. Yet it also testifies to an undercurrent belief that the ability to effectively prevent an attack would strengthen an organisation’s security posture.
 
For further information on our company, or to book your Deep Instinct Intro/Demo, please visit our website: www.deepinstinct.com
Sign up to one of our upcoming webinars here, we will be hosting 3 Webinars over the next 10 days.
 

Nick Hemsley
Enterprise Inside Sales, EMEA

M : +44 7813 04 55 44
Nickh@deepinstinct.com

Nick Hemsley
deep Instinct
+44 7813 045544
email us here


Source: EIN Presswire